<DOC>
	<DOCNO>NCT01290913</DOCNO>
	<brief_summary>This pilot feasibility study , use Xolair pretreatment oral peanut desensitization .</brief_summary>
	<brief_title>Xolair Enhances Oral Desensitization Peanut Allergic Patients</brief_title>
	<detailed_description>We hypothesize pretreatment anti-IgE mAb greatly reduce side effect allergic reaction occur oral desensitization peanut enhance development oral tolerance patient severe peanut allergy . We follow patient 5 year follow study completion .</detailed_description>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>1 . Patients severe peanut allergy , age 725 year , history significant clinical symptom within 1 hr peanut ingestion . 2 . Total IgE &gt; 50 kU/L &lt; 2,0000 kU/L . 3 . Sensitivity peanut document positive skin prick test result RAST test peanut , 20 kU/L low limit eligibility . 4 . Patients must also fail double blind food challenge peanut dose 100 mg less ( cumulative dose 186 mg ) , minimal reaction placebo challenge . 5 . All female subject childbearing potential require provide urine sample pregnancy test must negative one week allow participate study . 6 . Subjects must plan remain study area trial . 7 . Subjects and/or parent must train proper use EpiPen allow enroll study . Due risk serious systemic anaphylactic reaction peanut study , exclude : 1 . Patients acute infection , autoimmune disease , severe cardiac disease , treat betaadrenergic antagonistic drug ( betablockers , increase risk serious symptom anaphylaxis ) . 2 . Subjects history severe anaphylaxis peanut require intubation admission ICU , frequent urticaria , history consistent poorly control persistent asthma . 3 . Total IgE &gt; 2,000 IU/mL . 4 . Subjects unstable angina , significant arrhythmia , uncontrolled hypertension , chronic sinusitis , chronic immunological disease mind investigator might interfere evaluation administration test drug pose additional risk subject e.g . gastrointestinal gastroesophageal disease , chronic infection , scleroderma , hepatic gallbladder disease , chronic nonallergic pulmonary disease . 5 . Subject FEV1 PEF le 80 % predict without controller medication ( able perform maneuver ) screening , oral desensitization visit , food challenge visit . 6 . Subjects receive experimental drug last 30 day prior admission study plan use experimental drug study , current user oral , intramuscular , intravenous corticosteroid , tricyclic antidepressant , use medication could induce adverse gastrointestinal reaction study . 7 . Subjects refuse sign EpiPen Training Form . 8 . Pregnant breastfeeding female . 9 . Subjects severe food associate eczema , dermatitis herpetiformis , eosinophilic esophagitis , eosinophilic enteritis , proctocolitis , food protein induce enterocolitis syndrome ( FPIES ) gastrointestinal disease . These requirement necessary limit study patient primarily IgE mediate peanut allergy , exclude patient peanut sensitivity mediate cellular/T cell ( nonIgE mediate ) mechanism .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>peanut allergy</keyword>
	<keyword>Xolair</keyword>
</DOC>